Aerobic Exercise Attenuates Doxorubicin-Induced Cardiomyopathy by Suppressing NLRP3 Inflammasome Activation in a Rat Model
Abstract
:1. Introduction
2. Results
2.1. General Characteristics and Cardiac Morphology Associated with Dox Treatment
2.2. Cardiac Systolic Function and Blood Pressure Properties of Doxorubicin-Treated Rats
2.3. NLRP3 Signaling Activation in the Heart after DOX Treatment
3. Discussion
4. Materials and Methods
4.1. Ethical Approval
4.2. Materials
4.3. Animal
4.4. Exercise Training Program
4.5. Non-Invasive Blood Pressure Measurement
4.6. Echocardiographic Measurement
4.7. Histopathological Examination
4.8. Western Blot Analysis
4.9. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Tsao, C.W.; Aday, A.W.; Almarzooq, Z.I.; Anderson, C.A.M.; Arora, P.; Avery, C.L.; Baker-Smith, C.M.; Beaton, A.Z.; Boehme, A.K.; Buxton, A.E.; et al. Heart Disease and Stroke Statistics-2023 Update: A Report from the American Heart Association. Circulation 2023, 147, e93–e621. [Google Scholar] [PubMed]
- Pinckard, K.; Baskin, K.K.; Stanford, K.I. Effects of Exercise to Improve Cardiovascular Health. Front. Cardiovasc. Med. 2019, 6, 69. [Google Scholar] [CrossRef]
- Vega, R.B.; Konhilas, J.P.; Kelly, D.P.; Leinwand, L.A. Molecular Mechanisms Underlying Cardiac Adaptation to Exercise. Cell Metab. 2017, 25, 1012–1026. [Google Scholar] [CrossRef] [PubMed]
- Ashor, A.W.; Lara, J.; Siervo, M.; Celis-Morales, C.; Oggioni, C.; Jakovljevic, D.G.; Mathers, J.C. Exercise modalities and endothelial function: A systematic review and dose-response meta-analysis of randomized controlled trials. Sports Med. 2015, 45, 279–296. [Google Scholar] [CrossRef]
- Songbo, M.; Lang, H.; Xinyong, C.; Bin, X.; Ping, Z.; Liang, S. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol. Lett. 2019, 307, 41–48. [Google Scholar] [CrossRef]
- Kabel, A.M.; Salama, S.A.; Adwas, A.A.; Estfanous, R.S. Targeting Oxidative Stress, NLRP3 Inflammasome, and Autophagy by Fraxetin to Combat Doxorubicin-Induced Cardiotoxicity. Pharmaceuticals 2021, 14, 1188. [Google Scholar] [CrossRef]
- Zhang, W.; Fan, Z.; Wang, F.; Yin, L.; Wu, J.; Li, D.; Song, S.; Wang, X.; Tang, Y.; Huang, C. Tubeimoside I Ameliorates Doxorubicin-Induced Cardiotoxicity by Upregulating SIRT3. Oxid. Med. Cell Longev. 2023, 2023, 9966355. [Google Scholar] [CrossRef]
- Zhang, L.; Jiang, Y.-H.; Fan, C.; Zhang, Q.; Jiang, Y.-H.; Li, Y.; Xue, Y.-T. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis. Biomed. Pharmacother. 2021, 143, 112133. [Google Scholar] [CrossRef]
- Wang, Y.; Gao, W.; Shi, X.; Ding, J.; Liu, W.; He, H.; Wang, K.; Shao, F. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 2017, 547, 99–103. [Google Scholar] [CrossRef] [PubMed]
- Mauro, A.G.; Bonaventura, A.; Mezzaroma, E.; Quader, M.; Toldo, S. NLRP3 Inflammasome in Acute Myocardial Infarction. J. Cardiovasc. Pharmacol. 2019, 74, 175–187. [Google Scholar] [CrossRef]
- Zhou, W.; Chen, C.; Chen, Z.; Liu, L.; Jiang, J.; Wu, Z.; Zhao, M.; Chen, Y. NLRP3: A Novel Mediator in Cardiovascular Disease. J. Immunol. Res. 2018, 2018, 5702103. [Google Scholar] [CrossRef]
- Abbate, A.; Toldo, S.; Marchetti, C.; Kron, J.; Van Tassell, B.W.; Dinarello, C.A. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ. Res. 2020, 126, 1260–1280. [Google Scholar] [CrossRef] [PubMed]
- Phungphong, S.; Kijtawornrat, A.; Wattanapermpool, J.; Bupha-Intr, T. Regular exercise modulates cardiac mast cell activation in ovariectomized rats. J. Physiol. Sci. 2016, 66, 165–173. [Google Scholar] [CrossRef] [PubMed]
- Petersen, A.M.W.; Pedersen, B.K. The anti-inflammatory effect of exercise. J. Appl. Physiol. 2005, 98, 1154–1162. [Google Scholar] [CrossRef] [PubMed]
- Smart, N.A.; Larsen, A.I.; Le Maitre, J.P.; Ferraz, A.S. Effect of Exercise Training on Interleukin-6, Tumour Necrosis Factor Alpha and Functional Capacity in Heart Failure. Cardiol. Res. Pract. 2011, 2011, 532620. [Google Scholar] [CrossRef] [PubMed]
- Kong, C.Y.; Guo, Z.; Song, P.; Zhang, X.; Yuan, Y.P.; Teng, T.; Yan, L.; Tang, Q.Z. Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death. Int. J. Biol. Sci. 2022, 18, 760–770. [Google Scholar] [CrossRef]
- Shi, S.; Chen, Y.; Luo, Z.; Nie, G.; Dai, Y. Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell Commun. Signal 2023, 21, 61. [Google Scholar] [CrossRef]
- Kobayashi, M.; Usui, F.; Karasawa, T.; Kawashima, A.; Kimura, H.; Mizushina, Y.; Shirasuna, K.; Mizukami, H.; Kasahara, T.; Hasebe, N.; et al. NLRP3 Deficiency Reduces Macrophage Interleukin-10 Production and Enhances the Susceptibility to Doxorubicin-induced Cardiotoxicity. Sci. Rep. 2016, 6, 26489. [Google Scholar] [CrossRef]
- Wei, S.; Ma, W.; Li, X.; Jiang, C.; Sun, T.; Li, Y.; Zhang, B.; Li, W. Involvement of ROS/NLRP3 Inflammasome Signaling Pathway in Doxorubicin-Induced Cardiotoxicity. Cardiovasc. Toxicol. 2020, 20, 507–519. [Google Scholar] [CrossRef]
- Ping, Z.; Fangfang, T.; Yuliang, Z.; Xinyong, C.; Lang, H.; Fan, H.; Jun, M.; Liang, S. Oxidative Stress and Pyroptosis in Doxorubicin-Induced Heart Failure and Atrial Fibrillation. Oxid. Med. Cell Longev. 2023, 2023, 4938287. [Google Scholar] [CrossRef]
- Meng, L.; Lin, H.; Zhang, J.; Lin, N.; Sun, Z.; Gao, F.; Luo, H.; Ni, T.; Luo, W.; Chi, J.; et al. Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3. J. Mol. Cell Cardiol. 2019, 136, 15–26. [Google Scholar] [CrossRef] [PubMed]
- Palmieri, V.; Vietri, M.T.; Montalto, A.; Montisci, A.; Donatelli, F.; Coscioni, E.; Napoli, C. Cardiotoxicity, Cardioprotection, and Prognosis in Survivors of Anticancer Treatment Undergoing Cardiac Surgery: Unmet Needs. Cancers 2023, 15, 2224. [Google Scholar] [CrossRef]
- Afonso, A.I.; Amaro-Leal, Â.; Machado, F.; Rocha, I.; Geraldes, V. Doxorubicin Dose-Dependent Impact on Physiological Balance—A Holistic Approach in a Rat Model. Biology 2023, 12, 1031. [Google Scholar] [CrossRef]
- Phungphong, S.; Kijtawornrat, A.; Kampaengsri, T.; Wattanapermpool, J.; Bupha-Intr, T. Comparison of exercise training and estrogen supplementation on mast cell-mediated doxorubicin-induced cardiotoxicity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2020, 318, R829–R842. [Google Scholar] [CrossRef] [PubMed]
- Podyacheva, E.; Danilchuk, M.; Toropova, Y. Molecular mechanisms of endothelial remodeling under doxorubicin treatment. Biomed. Pharmacother. 2023, 162, 114576. [Google Scholar] [CrossRef]
- Lee, J.; Lee, Y.; LaVoy, E.C.; Umetani, M.; Hong, J.; Park, Y. Physical activity protects NLRP3 inflammasome-associated coronary vascular dysfunction in obese mice. Physiol. Rep. 2018, 6, e13738. [Google Scholar] [CrossRef]
- Mardare, C.; Krüger, K.; Liebisch, G.; Seimetz, M.; Couturier, A.; Ringseis, R.; Wilhelm, J.; Weissmann, N.; Eder, K.; Mooren, F.-C. Endurance and Resistance Training Affect High Fat Diet-Induced Increase of Ceramides, Inflammasome Expression, and Systemic Inflammation in Mice. J. Diabetes Res. 2016, 2016, 4536470. [Google Scholar] [CrossRef]
- ZhuGe, D.L.; Javaid, H.M.A.; Sahar, N.E.; Zhao, Y.Z.; Huh, J.Y. Fibroblast growth factor 2 exacerbates inflammation in adipocytes through NLRP3 inflammasome activation. Arch. Pharm. Res. 2020, 43, 1311–1324. [Google Scholar] [CrossRef]
- Zhang, X.; He, Q.; Huang, T.; Zhao, N.; Liang, F.; Xu, B.; Chen, X.; Li, T.; Bi, J. Treadmill Exercise Decreases Aβ Deposition and Counteracts Cognitive Decline in APP/PS1 Mice, Possibly via Hippocampal Microglia Modifications. Front. Aging Neurosci. 2019, 11, 78. [Google Scholar] [CrossRef]
- Benincasa, G.; Coscioni, E.; Napoli, C. Cardiovascular risk factors and molecular routes underlying endothelial dysfunction: Novel opportunities for primary prevention. Biochem. Pharmacol. 2022, 202, 115108. [Google Scholar] [CrossRef]
- Javaid, H.M.A.; Sahar, N.E.; ZhuGe, D.L.; Huh, J.Y. Exercise Inhibits NLRP3 Inflammasome Activation in Obese Mice via the Anti-Inflammatory Effect of Meteorin-like. Cells 2021, 10, 3480. [Google Scholar] [CrossRef] [PubMed]
- Sloan, R.P.; Shapiro, P.A.; DeMeersman, R.E.; Bagiella, E.; Brondolo, E.N.; McKinley, P.S.; Slavov, I.; Fang, Y.; Myers, M.M. The effect of aerobic training and cardiac autonomic regulation in young adults. Am. J. Public. Health 2009, 99, 921–928. [Google Scholar] [CrossRef] [PubMed]
- Docherty, S.; Harley, R.; McAuley, J.J.; Crowe, L.A.N.; Pedret, C.; Kirwan, P.D.; Siebert, S.; Millar, N.L. The effect of exercise on cytokines: Implications for musculoskeletal health: A narrative review. BMC Sports Sci. Med. Rehabil. 2022, 14, 5. [Google Scholar] [CrossRef] [PubMed]
- González-Moro, A.; Valencia, I.; Shamoon, L.; Sánchez-Ferrer, C.F.; Peiró, C.; de la Cuesta, F. NLRP3 Inflammasome in Vascular Disease: A Recurrent Villain to Combat Pharmacologically. Antioxidants 2022, 11, 269. [Google Scholar] [CrossRef]
- Lv, S.; Wang, H.; Li, X. The Role of the Interplay Between Autophagy and NLRP3 Inflammasome in Metabolic Disorders. Front. Cell Dev. Biol. 2021, 9, 634118. [Google Scholar] [CrossRef]
- Joseph, A.M.; Adhihetty, P.J.; Leeuwenburgh, C. Beneficial effects of exercise on age-related mitochondrial dysfunction and oxidative stress in skeletal muscle. J. Physiol. 2016, 594, 5105–5123. [Google Scholar] [CrossRef]
- Raneros, A.B.; Bernet, C.R.; Flórez, A.B.; Suarez-Alvarez, B. An Epigenetic Insight into NLRP3 Inflammasome Activation in Inflammation-Related Processes. Biomedicines 2021, 9, 1614. [Google Scholar] [CrossRef]
- Scott, J.M.; Khakoo, A.; Mackey, J.R.; Haykowsky, M.J.; Douglas, P.S.; Jones, L.W. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: Current evidence and underlying mechanisms. Circulation 2011, 124, 642–650. [Google Scholar] [CrossRef]
- Ascensão, A.; Magalhães, J.; Soares, J.; Ferreira, R.; Neuparth, M.; Marques, F.; Oliveira, J.; Duarte, J. Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. Int. J. Cardiol. 2005, 100, 451–460. [Google Scholar] [CrossRef]
- Chicco, A.J.; Hydock, D.S.; Schneider, C.M.; Hayward, R. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J. Appl. Physiol. 2006, 100, 519–527. [Google Scholar] [CrossRef]
- Hydock, D.S.; Wonders, K.Y.; Schneider, C.M.; Hayward, R. Voluntary wheel running in rats receiving doxorubicin: Effects on running activity and cardiac myosin heavy chain. Anticancer. Res. 2009, 29, 4401–4407. [Google Scholar]
- Heon, S.; Bernier, M.; Servant, N.; Dostanic, S.; Wang, C.; Kirby, G.M.; Alpert, L.; Chalifour, L.E. Dexrazoxane does not protect against doxorubicin-induced damage in young rats. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H499–H506. [Google Scholar] [CrossRef] [PubMed]
- Combs, A.B.; Hudman, S.L.; Bonner, H.W. Effect of exercise stress upon the acute toxicity of adriamycin in mice. Res. Commun. Chem. Pathol. Pharmacol. 1979, 23, 395–398. [Google Scholar] [PubMed]
- Wang, P.; Li, C.G.; Qi, Z.; Cui, D.; Ding, S. Acute exercise stress promotes Ref1/Nrf2 signalling and increases mitochondrial antioxidant activity in skeletal muscle. Exp. Physiol. 2016, 101, 410–420. [Google Scholar] [CrossRef]
- Muthusamy, V.R.; Kannan, S.; Sadhaasivam, K.; Gounder, S.S.; Davidson, C.J.; Boeheme, C.; Hoidal, J.R.; Wang, L.; Rajasekaran, N.S. Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardium. Free Radic. Biol. Med. 2012, 52, 366–376. [Google Scholar] [CrossRef] [PubMed]
- Fasipe, B.; Li, S.; Laher, I. Harnessing the cardiovascular benefits of exercise: Are Nrf2 activators useful? Sports Med. Health Sci. 2021, 3, 70–79. [Google Scholar] [CrossRef]
- Bedford, T.G.; Tipton, C.M.; Wilson, N.C.; Oppliger, R.A.; Gisolfi, C.V. Maximum oxygen consumption of rats and its changes with various experimental procedures. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 1979, 47, 1278–1283. [Google Scholar] [CrossRef]
- Bupha-Intr, T.; Wattanapermpool, J. Cardioprotective effects of exercise training on myofilament calcium activation in ovariectomized rats. J. Appl. Physiol. 2004, 96, 1755–1760. [Google Scholar] [CrossRef]
- Vutthasathien, P.; Wattanapermpool, J. Regular exercise improves cardiac contractile activation by modulating MHC isoforms and SERCA activity in orchidectomized rats. J. Appl. Physiol. 2015, 119, 831–839. [Google Scholar] [CrossRef]
- Hayward, R.; Hydock, D.S. Doxorubicin cardiotoxicity in the rat: An in vivo characterization. J. Am. Assoc. Lab. Anim. Sci. 2007, 46, 20–32. [Google Scholar]
- Kubota, Y.; Umegaki, K.; Kagota, S.; Tanaka, N.; Nakamura, K.; Kunitomo, M.; Shinozuka, K. Evaluation of Blood Pressure Measured by Tail-Cuff Methods (without Heating) in Spontaneously Hypertensive Rats. Biol. Pharm. Bull. 2006, 29, 1756–1758. [Google Scholar] [CrossRef] [PubMed]
- Guo, R.; Hua, Y.; Ren, J.; Bornfeldt, K.E.; Nair, S. Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity. Cell Death Dis. 2018, 9, 692. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Xie, Y.H.; Yang, Q.; Wang, S.W.; Zhang, B.L.; Wang, J.B.; Cao, W.; Bi, L.L.; Sun, J.Y.; Miao, S.; et al. Cardioprotective effect of paeonol and danshensu combination on isoproterenol-induced myocardial injury in rats. PLoS ONE 2012, 7, e48872. [Google Scholar] [CrossRef]
Parameters | Saline Injection | Doxorubicin Injection | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sedentary (n = 8) | Exercise (n = 8) | Sedentary (n = 8) | Exercise (n = 8) | |||||||||
Body weight, BW (g) | 667 | ± | 57.0 | 602 | ± | 10.5 * | 613 | ± | 39.3 * | 568 | ± | 27.3 * |
Heart weight, HW (g) | 1.479 | ± | 0.143 | 1.593 | ± | 0.055 * | 1.223 | ± | 0.040 * | 1.394 | ± | 0.075 † |
Tibial length, TL (cm) | 4.54 | ± | 0.05 | 4.53 | ± | 0.03 | 4.50 | ± | 0.04 | 4.53 | ± | 0.04 |
Soleus weight, SW (g) | 0.448 | ± | 0.021 | 0.453 | ± | 0.013 | 0.419 | ± | 0.021 | 0.456 | ± | 0.025 |
Kidney weight, KW (g) | 1.969 | ± | 0.044 | 1.864 | ± | 0.055 | 1.774 | ± | 0.035 * | 1.659 | ± | 0.052 † |
HW/BW (×100) | 0.221 | ± | 0.010 | 0.265 | ± | 0.004 * | 0.219 | ± | 0.005 | 0.246 | ± | 0.007 # |
HW/TL (g/cm) | 0.323 | ± | 0.009 | 0.352 | ± | 0.004 * | 0.297 | ± | 0.005 * | 0.308 | ± | 0.006 † |
SW/BW (×100) | 0.067 | ± | 0.004 | 0.075 | ± | 0.002 | 0.068 | ± | 0.003 | 0.080 | ± | 0.004 |
SW/TL (g/cm) | 0.099 | ± | 0.005 | 0.100 | ± | 0.003 | 0.093 | ± | 0.005 | 0.101 | ± | 0.005 |
KW/BW (×100) | 0.296 | ± | 0.003 | 0.309 | ± | 0.009 | 0.290 | ± | 0.005 | 0.292 | ± | 0.006 |
KW/TL (g/cm) | 0.434 | ± | 0.010 | 0.411 | ± | 0.012 | 0.394 | ± | 0.007 * | 0.366 | ± | 0.010 # |
Parameters | Saline Injection | Doxorubicin Injection | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sedentary (n = 8) | Exercise (n = 8) | Sedentary (n = 8) | Exercise (n = 8) | |||||||||
LVPW; s (mm) | 0.288 | ± | 0.016 | 0.306 | ± | 0.019 | 0.229 | ± | 0.018 | 0.248 | ± | 0.014 † |
LVPW; d (mm) | 0.306 | ± | 0.025 | 0.274 | ± | 0.014 | 0.239 | ± | 0.016 | 0.245 | ± | 0.009 † |
IVS; s (mm) | 0.308 | ± | 0.010 | 0.338 | ± | 0.012 | 0.231 | ± | 0.011 * | 0.248 | ± | 0.015 † |
IVS; d (mm) | 0.185 | ± | 0.013 | 0.221 | ± | 0.008 | 0.187 | ± | 0.012 | 0.199 | ± | 0.008 |
LVID; s (mm) | 0.331 | ± | 0.017 | 0.303 | ± | 0.020 | 0.450 | ± | 0.031 * | 0.394 | ± | 0.015 † |
LVID; d (mm) | 0.594 | ± | 0.020 | 0.586 | ± | 0.027 | 0.659 | ± | 0.049 | 0.606 | ± | 0.019 |
LV mass (g) | 1.135 | ± | 0.114 | 1.121 | ± | 0.084 | 1.034 | ± | 0.072 | 0.984 | ± | 0.048 |
LV mass/TL (g/cm) | 0.250 | ± | 0.025 | 0.249 | ± | 0.017 | 0.227 | ± | 0.015 | 0.218 | ± | 0.011 |
Relative wall thickness | 0.839 | ± | 0.065 | 0.863 | ± | 0.067 | 0.682 | ± | 0.081 | 0.740 | ± | 0.040 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Suthivanich, P.; Boonhoh, W.; Sumneang, N.; Punsawad, C.; Cheng, Z.; Phungphong, S. Aerobic Exercise Attenuates Doxorubicin-Induced Cardiomyopathy by Suppressing NLRP3 Inflammasome Activation in a Rat Model. Int. J. Mol. Sci. 2024, 25, 9692. https://doi.org/10.3390/ijms25179692
Suthivanich P, Boonhoh W, Sumneang N, Punsawad C, Cheng Z, Phungphong S. Aerobic Exercise Attenuates Doxorubicin-Induced Cardiomyopathy by Suppressing NLRP3 Inflammasome Activation in a Rat Model. International Journal of Molecular Sciences. 2024; 25(17):9692. https://doi.org/10.3390/ijms25179692
Chicago/Turabian StyleSuthivanich, Phichaya, Worakan Boonhoh, Natticha Sumneang, Chuchard Punsawad, Zhaokang Cheng, and Sukanya Phungphong. 2024. "Aerobic Exercise Attenuates Doxorubicin-Induced Cardiomyopathy by Suppressing NLRP3 Inflammasome Activation in a Rat Model" International Journal of Molecular Sciences 25, no. 17: 9692. https://doi.org/10.3390/ijms25179692